Wissenschaftliche Forschung

Zusammenfassung

Phase 2 double-blind randomized controlled trial comparing psilocybin with escitalopram for moderate-to-severe major depressive disorder. While the primary outcome showed no significant difference, secondary outcomes favored psilocybin over the 6-week period.